Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

Comment by redwings6on Jan 10, 2016 2:35pm
123 Views
Post# 24444767

RE:Analyst Recommendation

RE:Analyst RecommendationHere is the interpretation from 5i (Dec 8/15) December 08, 2015 (asked by Neil) Question: What do you think about MSL for a 10 year hold? I have a small position and I'm wondering if its worth holding long term. Thanks, Neil 5i Research Answer: On the recent quarter: Results were decent enough. Sales rose 87% from the year prior and EBITDA was up 144%. UK sales were strong. New product launches were good, with some other products hurt by new generics in the market. EBITDA forecast for 2016 is $30 million. Financial liquidity remains high, but there is still a net debt position. The forecast seems reasonable, and the stock is fairly cheap if it hits its EBITDA forecast. The results did miss estimates, so we would not expect much stock excitement on them. We think it is interesting and probably fine to hold. Not sure on the time frame, though, as it will need to build out its product portfolio somewhat to maintain growth over a decade.
<< Previous
Bullboard Posts
Next >>